Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088

被引：2
|
作者：
Loong, H. H. F. [1 ]
Daniele, G. [2 ]
Yang, T-Y. [3 ]
Leal, T. A. [4 ]
Goto, K. [5 ]
Shinno, Y. [6 ]
Nishino, K. [7 ]
Sakamoto, T. [8 ]
Felip, E. [9 ]
Ruffinelli, J. C. [10 ]
Gallot, N. [11 ]
Wang, Z. [12 ]
Chen, C. [13 ]
Brennan, B. [13 ]
Pu, S-F. [14 ]
Kornacker, M. [15 ]
Grassi, P. [16 ]
Le, X. [17 ]
Tan, D. S. W. [18 ]
Goh, B-C. [19 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Fdn Policlin Univ Agostino Gemelli IRCC, Phase 1 Unit, Rome, Italy
[3] Taichung Vet Gen Hosp, Chest Med, Taichung, Taiwan
[4] Emory Univ, Hematol & Oncol, Atlanta, GA USA
[5] Natl Canc Ctr Hosp East, Thorac Oncol, Kashiwa, Chiba, Japan
[6] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
[7] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan
[8] Tottori Univ, Dept Multidisciplinary Internal Med, Div Resp Med & Rheumatol, Tottori, Japan
[9] Vall dHebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain
[10] Hosp Duran & Reynals, Dept Med Oncol, ICO Inst Catala Oncol Hosp, Lhospitalet De Llobregat, Spain
[11] ClinBAY Ltd, Stat, Limassol, Cyprus
[12] Bayer HealthCare Pharmaceut Inc, Oncol, Cambridge, MA USA
[13] Bayer Healthcare Pharmaceut Inc, Clin Pharmacol, Whippany, NJ USA
[14] Bayer HealthCare Pharmaceut Inc, Benefit Risk Management, Pharmacovigilance, Whippany, NJ USA
[15] Bayer Consumer Care, Early Clin Dev Oncol, Basel, Switzerland
[16] Bayer SpA, RED Oncol, Milan, Italy
[17] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[18] Natl Canc Ctr Singapore, Dept Med Oncol, Singapore, Singapore
[19] Natl Univ Canc Inst, Dept Hematol Oncol, Singapore, Singapore
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2409
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1320MO
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)
    Choi, Dae-Ho
    Jung, Hyun Ae
    Park, Sehhoon
    Sun, Jong -Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Lee, Se-Hoon
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (12) : 2448 - 2459
  • [22] High activity of poziotinib in G778_P780dup HER2 exon 20 insertion mutations in non-small cell lung cancer (NSCLC)
    Le, X.
    Sun, S.
    Haura, E.
    Bertino, E.
    Baik, C.
    Mamdani, H.
    Leu, S.
    Thiagalingam, A.
    Kokhreidze, J.
    Lebel, F.
    Socinski, M. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1084 - S1085
  • [23] A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome
    Cognigni, Valeria
    Capelletto, Enrica
    Bordi, Paola
    Pavese, Valeria
    Carfi, Federica Maria
    Gelsomino, Francesco
    De Giglio, Andrea
    Chiari, Rita
    Minari, Roberta
    Ambrosini, Enrico
    Percesepe, Antonio
    Giachino, Daniela
    Bironzo, Paolo
    Tiseo, Marcello
    TUMORI JOURNAL, 2024,
  • [24] A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer
    Yang, Zandong
    Tchekmedyian, Nishan
    Chu, David T.
    Reddy, Guru
    Bhat, Gajanan
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies
    Bai, Qianming
    Wang, Jialei
    Zhou, Xiaoyan
    CANCER TREATMENT REVIEWS, 2023, 120
  • [26] Characterization of GI toxicities and their impact on efficacy in patients (pts) with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) treated with mobocertinib (TAK-788) who previously received platinum chemotherapy
    Nguyen, D.
    Ramalingam, S. S.
    Spira, A.
    Riely, G. J.
    Kim, T. M.
    Yang, J. C-H.
    Piotrowska, Z.
    Campelo, M. R. Garcia
    Felip, E.
    Bazhenova, L.
    Jin, S.
    Griffin, C.
    Diderichsen, P. M.
    Gupta, N.
    Bunn, V.
    Lin, J.
    Churchill, E. N.
    Mehta, M.
    Zhou, C.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S968 - S969
  • [27] Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation.
    Gao, Guanghui
    Li, Xingya
    Wang, Qiming
    Zhang, Yiping
    Chen, Jianhua
    Shu, Yongqian
    Hu, Yanping
    Fan, Yun
    Fang, Jian
    Chen, Gongyan
    Zhao, Jun
    He, Jianxing
    Wu, Fengying
    Zou, Jianjun
    Zhu, Xiaoyu
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Real-world frequency of non-small cell lung cancer with ERBB2 exon 20 insertion (Exon20ins) mutations by site of insertion.
    Yang, Li
    Huang, Tanxiao
    Qu, Yuan
    Wang, Qichen
    Teng, Jiaman
    Yang, Bo
    Chen, Shifu
    Kong, Feng-Ming Spring
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] TY-4028: a novel, targeted therapy for non small-cell lung cancer with EGFR exon 20 or HER2 exon 20 insertion mutations
    Li, Jun
    Niu, Chengshan
    Guo, Zhongwei
    Wang, Huan
    Zheng, Bailu
    Dou, Yuge
    Liang, Apeng
    Ji, Kaige
    Dong, Shengli
    Li, Meihua
    Zhao, Yanchao
    Zhang, Yazhen
    Gong, Aishen
    Liu, Hao
    Hu, Xinmiao
    Su, Hui
    Jiang, Mingyu
    Chen, Shaoqing
    Chen, Xiugui
    Wu, Yusheng
    CANCER RESEARCH, 2023, 83 (07)
  • [30] Epidermal growth factor receptor (EGFR) testing and treatment patterns associated with diagnosis of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) in the US
    Piotrowska, Z.
    Lin, M.
    Yin, Y.
    Curran, E.
    Crossland, V.
    Wu, Y.
    Ou, S-H. I.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1011 - S1011
12345